John Goosey, MD
Ophthalmology · Houston, TXNPI 1215922406
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Recordati_rare_diseases_inc. at 58.6% of the total. Reporting peaked in 2022 at $16,146 and has fallen 95.1% since, to $791 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $81.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recordati_rare_diseases_inc.$17K
- Dompe US, Inc.$4K
- Alcon$2K
- AbbVie$1K
- Novartis$640
- Bausch & Lomb Americas Inc.$617
- plus $3K from 17 others
Across 55 payments — averaging $6820.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$129K
- Dompe Farmaceutici S.p.a.$89K
- Glaukos Corporation$72K
- Aerie Pharmaceuticals, Inc.$37K
- Dompe US, Inc.$32K
- Alcon Research LLC$16K
What the payments were for
- Consulting fees$14,91051%
- Speaking & faculty fees$4,30015%
- Travel & lodging$7733%
- Food & beverage$8,12728%
- Gifts$1,0404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recordati_rare_diseases_inc. | 4 | $17,088 |
| Dompe US, Inc. | 5 | $4,379 |
| Alcon | 50 | $1,673 |
| AbbVie(2 entities) | 91 | $1,444 |
| Novartis | 38 | $640 |
| Bausch & Lomb Americas Inc. | 25 | $617 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $594 |
| Sun Pharmaceutical Industries Inc. | 27 | $581 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $412 |
| Oyster Point Pharma, Inc. | 15 | $363 |
| Eyevance Pharmaceuticals LLC | 17 | $340 |
| Shire North American Group Inc | 12 | $170 |
| Kala Pharmaceuticals, Inc. | 8 | $149 |
| Tarsus Pharmaceuticals, Inc. | 6 | $140 |
| Thea Pharma Inc. | 6 | $119 |
| Harrow Eye, LLC | 4 | $107 |
| Ocular Therapeutix, Inc. | 5 | $90 |
| Rxsight Inc | 3 | $70 |
| Carl Zeiss Meditec, Inc. | 1 | $64 |
| Biotissue Holdings Inc. | 2 | $46 |
| Sight Sciences, Inc. | 1 | $23 |
| Eyepoint US, Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$1,500
- Clareon$150
- IC-8 Apthera IOL$147
- ReSTOR$141
- LenSx$138
- Tecnis Multifocal Family of 1-piece IOLS$120
- ENVISTA$118
- Catalys Laser System$110
- CATALYS SYSTEM$107
How this compares
$29,149 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 240 | $262,812 |
| XiidraLifitegrast | 86 | $96,637 |
| Cyclosporine | 120 | $70,839 |
| MieboPerfluorohexyloctane/Pf | 53 | $43,233 |
| LumiganBimatoprost | 78 | $35,283 |
| TyrvayaVarenicline Tartrate | 21 | $24,228 |
| Prednisolone Acetate | 647 | $21,668 |
| ProlensaBromfenac Sodium | 61 | $20,912 |
| FlarexFluorometholone Acetate | 153 | $20,195 |
| Lotemax SmLoteprednol Etabonate | 63 | $15,420 |
| Fluorometholone | 198 | $14,795 |
| Loteprednol Etabonate | 63 | $9,956 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $8,181 |
| Bromfenac Sodium | 36 | $5,674 |
| Ketorolac Tromethamine | 350 | $5,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,444 | $310,031360 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $617 | $139,870139 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate, Alrex | $594 | $49,768199 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $363 | $24,22821 claims |
| Eyevance Pharmaceuticals LLCFlarex | $340 | $20,195153 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $21 | $4,46914 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $581 | $3,48014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.